Shares of BeyondSpring (NASDAQ:BYSI) climbed more than 6% in premarket trading on Wednesday after the company reported a smaller loss from continuing operations and highlighted progress across its development pipeline.
The stock gained 6.47% following the earnings update.
Quarterly loss narrows year-on-year
BeyondSpring reported a net loss from continuing operations of $2.4 million for the three months ended March 31, 2026, compared with a loss of $2.6 million during the same quarter last year.
The company did not record any revenue during the quarter.
As of March 31, 2026, BeyondSpring held $7.9 million in cash, cash equivalents and short-term investments.
Research spending increases as development progresses
Research and development expenses rose to $1.1 million from $0.9 million a year earlier.
The company said the increase was driven by expanded drug manufacturing activities in preparation for potential future clinical studies.
General and administrative expenses declined to $1.1 million from $1.7 million in the prior-year period, mainly due to lower personnel-related and legal advisory costs.
Company highlights AACR 2026 data for Plinabulin
BeyondSpring pointed to new data presented at the AACR Annual Meeting 2026 showing that Plinabulin significantly improved both efficacy and tolerability in antibody-drug conjugate regimens based on topoisomerase inhibitors.
According to the company, preclinical findings demonstrated stronger complete response rates, improved survival outcomes and enhanced immune responses.
“Plinabulin continues to demonstrate the ability to enhance both efficacy and tolerability in ADC-based regimens, supporting its positioning as a potential backbone agent across a rapidly evolving treatment landscape,” said Lan Huang, co-founder, chair and chief executive officer of BeyondSpring.
SEED Therapeutics advances Phase 1 programme
At SEED Therapeutics, BeyondSpring advanced ST-01156, described as a novel RBM39 molecular glue degrader, into Phase 1 clinical development.
The company said the first dosing cohort has already been completed.
Additional data presented at AACR 2026 showed complete tumour eradication in an in vivo neuroblastoma model.
Discontinued operations weigh on overall results
BeyondSpring recorded a net loss from discontinued operations of $4.3 million during the quarter.
In the same period last year, the company reported net income from discontinued operations of $3.8 million.